Toshiba America Medical Systems is planning a full-court pressat this month's Radiological Society of North America meeting.In an effort to secure a greater U.S. market share, the Japanesevendor is introducing a range of new products, many of which
Toshiba America Medical Systems is planning a full-court pressat this month's Radiological Society of North America meeting.In an effort to secure a greater U.S. market share, the Japanesevendor is introducing a range of new products, many of which havebeen designed with input from U.S. clinicians, according to RaviSharma, vice president of marketing.
At the top of Toshiba's list of product introductions is Flexart,a new 0.5-tesla MRI scanner to be shown as a works-in-progress.Flexart uses a helium-only superconducting magnet designed forlow cryogen boil-off and low maintenance. The system is activelyshielded to reduce eddy currents and can be sited in a space assmall as 45 square meters, Sharma said.
"This has been developed mainly for community hospitalsand hospitals that are going to see high growth in the managed-careenvironment," he said.
Flexart will be priced at about $1 million and will be positionedas Toshiba's premium mid-field offering. The company will continueto sell MRT-50A, its existing mid-field product.
In CT, Toshiba will unveil Xpress/SX, an upgrade to the vendor'sXpress slip-ring CT scanner. The upgrade will add solid-statedetectors to Xpress, which enable faster helical scanning andimproved image quality, Sharma said.
The system is powered by a 48-kW generator with an output of400 mAs and runs a 3.5-million heat unit x-ray tube. Xpress/SXhas Food and Drug Administration marketing clearance. It willbe priced at about $1 million, Sharma said.
Other new product introductions include:
New Study Examines Short-Term Consistency of Large Language Models in Radiology
November 22nd 2024While GPT-4 demonstrated higher overall accuracy than other large language models in answering ACR Diagnostic in Training Exam multiple-choice questions, researchers noted an eight percent decrease in GPT-4’s accuracy rate from the first month to the third month of the study.
FDA Grants Expanded 510(k) Clearance for Xenoview 3T MRI Chest Coil in GE HealthCare MRI Platforms
November 21st 2024Utilized in conjunction with hyperpolarized Xenon-129 for the assessment of lung ventilation, the chest coil can now be employed in the Signa Premier and Discovery MR750 3T MRI systems.
FDA Clears AI-Powered Ultrasound Software for Cardiac Amyloidosis Detection
November 20th 2024The AI-enabled EchoGo® Amyloidosis software for echocardiography has reportedly demonstrated an 84.5 percent sensitivity rate for diagnosing cardiac amyloidosis in heart failure patients 65 years of age and older.